Private equity firm Nordic Capital acquired an 80% stake in Danish proteomics company Evosep to accelerate the firm's push into translational and clinical proteomics markets. CEO Morten Bern said the deal will support Evosep’s move from research-focused LC-MS separations toward higher-throughput platforms and clinical laboratory-developed tests. Evosep’s standardized separations and high-sensitivity LC systems (Evosep One, Eno) aim to raise proteomics throughput to levels comparable with transcriptomics, enabling pharma and clinical labs to adopt mass-spectrometry–based protein panels and proteoform monitoring. Nordic Capital cited prior investments in translational diagnostics as rationale for the partnership.